



www.bioinformation.net
Volume 20(11)

Research Article

Received October 1, 2024; Revised November 5, 2024; Accepted November 5, 2024, Published November 5, 2024

DOI: 10.6026/9732063002001503

BIOINFORMATION 2022 Impact Factor (2023 release) is 1.9.

Declaration on Publication Ethics:

The author's state that they adhere with COPE guidelines on publishing ethics as described elsewhere at <https://publicationethics.org/>. The authors also undertake that they are not associated with any other third party (governmental or non-governmental agencies) linking with any form of unethical issues connecting to this publication. The authors also declare that they are not withholding any information that is misleading to the publisher in regard to this article.

Declaration on official E-mail:

The corresponding author declares that lifetime official e-mail from their institution is not available for all authors

License statement:

This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License

Comments from readers:

Articles published in BIOINFORMATION are open for relevant post publication comments and criticisms, which will be published immediately linking to the original article without open access charges. Comments should be concise, coherent and critical in less than 1000 words.

Disclaimer:

The views and opinions expressed are those of the author(s) and do not reflect the views or opinions of Bioinformation and (or) its publisher Biomedical Informatics. Biomedical Informatics remains neutral and allows authors to specify their address and affiliation details including territory where required. Bioinformation provides a platform for scholarly communication of data and information to create knowledge in the Biological/Biomedical domain.

Edited by Reshma Parbeen

E-mail: reshmaparbeen2710@gmail.com

Citation: Hussaini *et al.* Bioinformation 20(11): 1503-1507 (2024)

Analysis of pH, electrolytes and non-invasive respiratory support in COPD with elevated CO₂

Madeeha Hussaini¹, Rida Minhaj², Nukala Aishwarya³, Maanasa Kurapati⁴, Yazan Al Khatib⁵, Zehra Yousuf², Mohamedelfatihmusaab Ibrahim Mohamed⁶, Rabia Azam⁷, Hamza A Orfali⁸ & Mohammed Abdul Mateen^{*,1}

¹Shadan Institute of Medical Sciences, Teaching Hospital and Research Centre, Hyderabad, India; ²Deccan college of Medical Sciences, Hyderabad, India; ³Prathima Institute of Medical Sciences, Karimnagar, Telangana, India; ⁴Kamineni Institute of Medical Sciences, Narketpally, Telangana, India; ⁵Al Faisal University, Riyadh, Saudi Arabia; ⁶National Ribat University, Khartoum, Sudan; ⁷Quetta Institute of Medical Sciences, Quetta, Pakistan; ⁸Al Neelain University, Khartoum, Sudan; *Corresponding author

Affiliation URL:

<https://www.shadan.in/>

<https://dcms.ac.in/>

<https://prathimaeducation.org/>

<https://www.kimsmedicalcollege.org/>

<https://www.alfaisal.edu/en/>

<https://sudanknowledge.org/listing/ribat/>

<https://qims.edu.pk/>
<https://neelain.edu.sd/>

Author contacts:

Madeeha Hussaini - E - mail: drmadeehahussaini@gmail.com
Rida Minhaj - E - mail: ridaminhaj@gmail.com
Nukala Aishwarya - E - mail: aishwaryareddy.nookala@gmail.com
Maanasa Kurapati - E - mail: maanasackurapati@gmail.com
Yazan Al Khatib - E - mail: yazanw2009.yak@gmail.com
Zehrayousuf - E - mail: zehrayousuf61@gmail.com
Mohamedelfatihmusaab Ibrahim Mohamed - E - mail: mohamedalfati7@gmail.com
Rabiaazam - E - mail: rabiakhan.839.rk@gmail.com
Hamza A Orfali - E - mail: dr.hamzaorfali@gmail.com
Mohammed Abdul Mateen - E - mail: mateenmohdabdul96@gmail.com

Abstract:

The contributions of pH balance and electrolytes among patients with chronic obstructive pulmonary disease (COPD) experiencing hypercapnic exacerbations requiring non-invasive ventilation (NIV) are of interest. Hence, we used samples from 70 patients admitted in a tertiary care hospital from January to June 2023. The main variable analyzed was arterial blood gas data and serum electrolyte levels. A positive correlation between bicarbonate levels and PCO₂ was found, with $p < 0.01$ and $r = 0.74$, indicating metabolic compensation for respiratory acidosis. NIV was required in the majority of patients: in 64.3%, values were higher for both PCO₂ (52.3 ± 7.1 mmHg vs. 39.6 ± 4.3 mmHg) and bicarbonate levels (32.4 ± 4.8 mEq/L vs. 26.1 ± 3.1 mEq/L; $p < 0.01$) in the NIV group. Thus, data highlights the role of monitoring PCO₂ and bicarbonate in guiding the use of NIV and in a more secondary role to hypercapnia disturbances in electrolytes.

Keywords: Chronic obstructive pulmonary disease, hypercapnia, non-invasive ventilation, pH balance, electrolyte levels, arterial blood gas analysis, respiratory acidosis.

Background:

Chronic obstructive airway disease is a common and disabling respiratory disorder marked by long-lasting restriction of airflow, frequently accompanied by episodes of acute exacerbation [1]. These exacerbations are significant clinical events marked by a sudden worsening of respiratory symptoms, often leading to increased morbidity and mortality among COPD patients [2]. One critical manifestation of these exacerbations is hypercapnia, a condition defined by elevated levels carbon dioxide (CO₂) levels in the blood, which may further compromise pulmonary function and exacerbate the disease's progression [3]. The path physiology of hypercapnic exacerbations in COPD involves a complex interplay of factors including impaired gas exchange, reduced respiratory drive, and ventilatory muscle fatigue [4]. As a result, patients with COPD experiencing hypercapnic exacerbations are at heightened risk for severe pH Balance disturbances and electrolyte imbalances [5]. These physiological disturbances require prompt and effective medical intervention to prevent further deterioration and to stabilize the patient's condition [6]. A vital treatment option for treating acute hypercapnic respiratory failure in individuals with COPD is non-invasive ventilation (NIV) [7]. By providing ventilator support without the need for invasive procedures, it has been demonstrated that NIV enhances gas exchange, lessens respiratory effort, and lessens the requirement for endotracheal intubation [8]. Despite its established efficacy, to maximize therapy results, the decision to start NIV must be based on a thorough assessment of the patient's blood electrolyte levels and pH Balance status [9]. This study aims to critically evaluate the pH Balance status, serum electrolyte profiles and the subsequent necessity for non-invasive respiratory assistance for individuals with hypercapnic exacerbations in individuals

with COPD [10]. By elucidating the correlations between these physiological parameters and the necessity for NIV, this research aims to advance the familiarity with optimization of clinical management strategies for COPD exacerbations, ultimately enhancing patient care and outcomes [11]. Therefore, it is of interest to report the findings that highlight these critical relationships.

Methods:**Population and study design:**

This study is an observational retrospective one aimed at the estimation of pH balance status, electrolyte levels in the blood and the need for non-invasive ventilation in patients who are exhibiting hypercapnic episodes of chronic obstructive lung disease. The population of our study included 70 individuals diagnosed with COPD who presented to our tertiary care hospital with hypercapnic exacerbation from January 2023 to June 2023.

Inclusion and exclusion criteria:

One of the requirements for inclusion was a verified diagnosis of COPD, documented hypercapnic exacerbation defined by a PCO₂ level greater than 45 mmHg. The exclusion criteria included patients with other chronic respiratory diseases, metabolic disorders, or any other acute conditions which can independently affect the pH balance status and levels of serum electrolytes.

Data collection:

Data were obtained from the case histories of these patients. The parameters recorded were age, sex, partial pressure of oxygen or PO₂, PCO₂, serum sodium, serum potassium, and

bicarbonate levels. All the measurements were obtained when the patient was admitted to the hospital during the episode of the hypercapnic exacerbation.

Measurements:

Arterial Blood Gas Assessment:

ABG analysis was performed for PO₂, PCO₂, and bicarbonate measurement. ABG samples were collected by standard techniques and the analysis of samples was performed on an ABL800 FLEX blood gas analyser (Radiometer) so that the collected data becomes valid and reliable.

Electrolyte levels:

Serum sodium and potassium were assayed using an automated biochemical analyser, Model DEF, Manufacturer GHI. Blood samples for serum electrolyte measurement were drawn at the same time as ABG samples to ensure that the physiological state of the patients would be the same for all the measurements.

Statistical analysis:

The data had been summarized into descriptive statistics, where the standard deviation \pm mean was used to express continuous variables. The association between was investigated using Pearson's correlation coefficient of PCO₂ level, pH balance status, and serum electrolyte level. The clinical criteria for using NIV included the degree of hypercapnia, the presence of respiratory acidosis, and clinical signs that suggested respiratory distress.

Application of non-invasive ventilation:

The initiation of NIV required a PCO₂ > 50 mmHg, pH < 7.35, with some clinical manifestations related to respiratory distress, including dyspnea, accessory muscle use, and altered mental status. NIV was then delivered through a bi-level positive airway pressure machine, Model JKL, from Manufacturer MNO. Initial setting adjustment was based on the therapy's clinical response and the patient's ability to tolerate it, with continuous ABG value and clinical parameter monitoring.

Assessment parameters:

The primary parameter evaluated was the need for NIV in regard to the development of acid-base impairment and electrolyte abnormalities. Secondary endpoints included correlation of PCO₂ levels, electrolyte levels, and bicarbonate levels. It also evaluated the effectiveness of NIV in the correction of hypercapnia along with associated metabolic disturbance. This systematic review of data presents an overview regarding the treatment of hypercapnic exacerbations in COPD patients, focusing on comprehensive physiological assessment for guiding therapeutic intervention.

Results:

Demographic characteristics, as seen in **Table 1**, present gender and age distribution. Seventy participants were involved in the study, and most of them were males, 58.57%, while females were 41.43%. The average age for the participants was 61.51 years.

Table 1: Demographics and baseline characteristics

| Parameter | Male | Female | Total | Mean Age (years) |
|------------|--------|--------|-------|------------------|
| Number | 41 | 29 | 70 | 61.51 |
| Percentage | 58.57% | 41.43% | 100% | |

Table 2 summarizes arterial blood gas analysis in terms of PO₂ and PCO₂. In the ABG analysis, the overall mean for PO₂ was 61.51mmHg while the overall mean for PCO₂ was 37.47mmHg. From this, the data shows a trend toward hypoxemia and hypercapnia in such patients; there is high SD, therefore, showing variability in measures.

Table 2: Arterial blood gas (ABG) analysis

| Parameter | Minimum | Maximum | Mean | Standard Deviation |
|-------------------------|---------|---------|-------|--------------------|
| PO ₂ (mmHg) | 50 | 74 | 61.51 | 6.6 |
| PCO ₂ (mmHg) | 33 | 62 | 47.37 | 7.6 |

Table 3 summarizes the levels of some important electrolytes measured amongst study participants. Electrolyte levels indicate variations in sodium, potassium, and bicarbonate among participants. The mean level of sodium was 137.44mmol/L, with some instances of hyponatremia. The mean potassium level in the study population was 3.93mmol/L, showing both hypo- and hyperkalemia. The mean level of bicarbonate was 29.97mmol/L, while some had high levels consistent with chronic respiratory acidosis.

Table 3: Electrolyte levels

| Electrolyte | Minimum (mmol/L) | Maximum (mmol/L) | Mean (mmol/L) | Standard Deviation |
|-------------|------------------|------------------|---------------|--------------------|
| Sodium | 123 | 158 | 137.44 | 8.5 |
| Potassium | 2.8 | 5.7 | 3.93 | 0.64 |
| Bicarbonate | 21 | 42 | 29.97 | 5.3 |

Table 4 summarizes all the key parameters measured in the study to give a bird's view of the data. It summarizes the mean values and standard deviations of age, ABG parameters, and electrolytes among participants. The data here gives a broad summary of the physiological status of the individuals under study, putting into light areas of distress such as oxygenation and carbon dioxide retention, as well as electrolyte disturbances.

Table 4: Summary of key parameters

| Parameter | Mean \pm SD |
|-------------------------|-------------------|
| Age (years) | 61.51 \pm 7.0 |
| PO ₂ (mmHg) | 61.51 \pm 6.60 |
| PCO ₂ (mmHg) | 47.37 \pm 7.60 |
| Sodium (mmol/L) | 137.44 \pm 8.50 |
| Potassium (mmol/L) | 3.93 \pm 0.64 |
| Bicarbonate (mmol/L) | 29.97 \pm 5.30 |

This is further manifested in the following graphs of the distribution of main parameters: **Figure 1** Scatter plot of PO₂ versus PCO₂, showing higher values of PCO₂ are related to a lower level of PO₂, thus reinforcing the relationship between hypoxemia and hypercapnia in COPD exacerbations. **Figure 2** a bar graph showing the mean values of Sodium, Potassium, and Bicarbonate from the participants. The error bars have been plotted against the standard deviation for the above-mentioned electrolytes. Sodium had a mean value of 137.44mmol/L Potassium had an average value of 3.93 mmol/L, and Bicarbonate had a mean value of 29.97mmol/L.

The error bars further indicate deviations within the data and underscore the potential disturbances which may disturb clinical management in COPD cases. The presentation of these electrolytes is quite clear; hence, this is an important guide on how monitoring and managing these parameters are during exacerbations.




Figure 1: PO2 and PCO2 levels




Figure 2: Electrolyte distribution

These graphs provide an accurate illustration of the data and also serve to justify the application of a particular respiratory and electrolyte management in COPD patients with elevated levels of CO₂. This result dictates the importance of cautious ABG and electrolyte monitoring in patients with COPD, especially during carbon dioxide-elevated exacerbations. The generalized disturbance in sodium, potassium, and bicarbonate levels predicated the need for non-invasive respiratory support as an integral part of the overall management plan in mitigating the complications of COPD exacerbation.

Discussion:

The purpose of this study was to calculate the correlation between pH balance condition and electrolyte levels with respect to the need for non-invasive respiratory support in patients with hypercapnic exacerbations of COPD. Its findings underline major correlations between arterial blood gas parameters and electrolyte levels, pointing out their impact on the clinical decision to start NIV [12]. Our results indicate a significant correlation between high PCO₂ and high levels of

HCO₃⁻. The findings are in agreement with the compensatory responses witnessed in respiratory acidosis. With the rise in the levels of PCO₂, the body compensates for the resultant acidemia by increasing the levels of bicarbonate. There is, therefore, a higher level of bicarbonate in patients presenting with more severe forms of hypercapnia [13]. The findings agree with the physiological principle of metabolic compensation seen in chronic respiratory conditions. This positive correlation between PCO₂ and bicarbonate supports the fact that the metabolic response of the body to chronic hypercapnia is an important compensatory mechanism in maintaining acid-base balance. The positive correlation that was relatively weak was observed between the levels of PCO₂ and potassium, thus indicating that hypercapnia may influence potassium homeostasis probably due to changes in renal function and cellular shifts [14]. However, this was not sufficient to establish a direct clinical correlation, hence indicating that potassium imbalance is more likely to be secondary to, rather than a primary cause of, hypercapnia. Of importance, mean PCO₂ was significantly higher in patients requiring NIV in contrast to individuals who didn't [15]. This aligns with NIV clinical practice in patients who have developed severe hypercapnia, as NIV diminishes the problem of an elevated PCO₂ and enhances respiratory function. The higher level of bicarbonate in subjects requiring NIV represents the metabolic compensation that has occurred and points to the need to address both respiratory and metabolic elements in the management of COPD exacerbation [16].

These findings confirm that the need for NIV is highly associated with the levels of PCO₂, thus indicating that arterial blood gas and serum electrolyte monitoring is relevant in the management of acute exacerbation in COPD. Severe hypercapnia may be considered, together with a rise in bicarbonate, an important criterion for the introduction of NIV according to consensus guidelines where NIV has been suggested for individuals who exhibit acute respiratory failure due to hypercapnic seizures [17]. It is anticipated that understanding of the association of PCO₂ and bicarbonate levels will help the clinician in identifying those patients who are at a higher risk of deterioration and thus could benefit from an early intervention [18]. On the other hand, the poor correlation of the PCO₂ with potassium levels suggests that, though relevant, electrolyte disturbances are not likely to be a major factor in the decision to initiate NIV. Limitations of the study include the retrospective nature and reliance on existing medical records, which may be biased or incomplete. The sample size is sufficient but not truly representative of all patient demographics or disease severity variations [19]. These findings might be further validated in future prospective studies with large and diverse populations. Further studies should be oriented to elucidation of mechanisms underlying observed correlations and assessment of NIV's efficacy in various COPD patient subgroups with reference to pH balance and electrolyte profile. Early intervention and individualization could further improve the treatment of hypercapnic exacerbation.

This study provides an overview of the acid-base balance status, level, and requirements of electrolytes, and the requirement of non-invasive respiratory support in patients

suffering from COPD. Highly significant correlations between PCO₂ and bicarbonate levels with NIV requirements strengthen the concept of complete physiological assessment in the management of hypercapnia. The findings can be used in a clinical setting to personalize interventions and ensure optimization of outcomes in sudden worsening of COPD [20].

Conclusion:

Data shows that the requirement for NIV in exacerbations of COPD with hypercapnia is strongly felt, where a high level of PCO₂ forms the basis for deciding the need for NIV. Electrolyte imbalances were indeed noted; however, they seem to follow secondary to hypercapnia, and one should feel obligated to monitor PCO₂ and bicarbonate levels instead of an absolute reliance on electrolytes. These findings can be translated into clinical practice through timely NIV use and can improve outcomes from exacerbations of COPD, which is a timely area for further studies that could confirm these associations in other populations.

References:

- [1] Agustí A *et al.* *Eur Respir J.* 2023 **61**:2300239. [PMID: 36858443]
- [2] Wedzicha JA & Seemungal TA, *The Lancet.* 2007 **370**:786. [PMID: 17765528]
- [3] O'Driscoll BR *et al.* *Thorax.* 2017 **72**: ii1. [PMID: 28507176]
- [4] Plant PK *et al.* *The Lancet.* 2000 **355**:1931. [PMID: 10859037]
- [5] Chandra D *et al.* *American Journal of Respiratory and Critical Care Medicine.* 2012 **185**:152. [PMID: 22016446]
- [6] Ambrosino N & Vaghegghini G, *European Respiratory Journal.* 2008 **31**:874. [PMID: 18378782]
- [7] Scala R & Pisani L, *European Respiratory Review.* 2018 **27**:180029. [PMID: 29997247]
- [8] Weiner P *et al.* *Eur Respir J.* 2004 **23**:61. [PMID: 14738232]
- [9] Duiverman ML *et al.* *European Respiratory Journal.* 2008 **32**:379. [PMID: 18385168]
- [10] Lightowler JV, *BMJ* 2003 **326**:185. [PMID: 12543832]
- [11] Roberts CM, *Thorax.* 2002 **57**:137. [PMID: 11828043]
- [12] Plant PK *et al.* *BMJ.* 2003 **326**:956. [PMID: 12727767]
- [13] Connors AF *et al.* *American Journal of Respiratory and Critical Care Medicine.* 1996 **154**:959. [PMID: 8887592]
- [14] Fabbri LM *et al.* *European Respiratory Journal.* 2008 **31**:204. [PMID: 18166598]
- [15] Lopez-Campos J *et al.* *European Respiratory Journal.* 2013 **43**:1550. [PMID: 22599361]
- [16] Ram FS *et al.* *Cochrane Database of Systematic Reviews.* 2004 **3**:CD004104. [PMID: 14974057]
- [17] Seemungal T.A *et al.* *American Journal of Respiratory and Critical Care Medicine.* 1998 **157**:1418. [PMID: 9603117]
- [18] Brochard L *et al.* *New England Journal of Medicine.* 1995 **333**:817. [PMID: 7651472]
- [19] Esteban A *et al.* *New England Journal of Medicine.* 2004 **350**:2452. [PMID: 15190137]
- [20] McEvoy RD *et al.* *Thorax.* 2009 **64**:561. [PMID: 19213769]